News & Updates

Show Multimedia Only

Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis

18 Jul 2024

Smoking and occupational dust exposure appear to contribute to an increased risk of idiopathic pulmonary fibrosis (IPF), according to a study.

Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis

18 Jul 2024

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

14 Jul 2024

Ivonescimab plus chemotherapy has a tolerable safety profile and appears to significantly prolong progression-free survival (PFS) in patients with nonsmall cell lung cancer (NSCLC) whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, according to interim data from the phase III HARMONi-A study.

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

14 Jul 2024

Certain antipsychotics tied to increased pneumonia risk

13 Jul 2024

Specific antipsychotic drugs such as high-dose quetiapine, high- and medium-dose clozapine, and high-dose olanzapine appear to be associated with a heightened risk of pneumonia among patients with schizophrenia, as shown in a study.

Certain antipsychotics tied to increased pneumonia risk

13 Jul 2024

Osimertinib extends PFS by 3.2 years in LAURA

12 Jul 2024 by

Osimertinib extends progression-free survival (PFS) sevenfold longer than placebo in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) following definitive chemoradiotherapy, as shown in the primary analysis of the phase III LAURA study presented at ASCO 2024. This breakthrough makes osimertinib the first EGFR inhibitor to show benefit in a stage III setting.

Osimertinib extends PFS by 3.2 years in LAURA

12 Jul 2024

Retrospective study validates nirsevimab role against RSV in infants

08 Jul 2024 by

A retrospective cohort study evaluating participants from Catalonia, Spain reinforces the potential of immunoprophylaxis with the novel monoclonal antibody nirsevimab in combating respiratory syncytial virus (RSV)-related outcomes in infants in the hospital and primary care settings.

Retrospective study validates nirsevimab role against RSV in infants

08 Jul 2024

Pamrevlumab disappoints in phase III trial

05 Jul 2024 by

The human monoclonal antibody pamrevlumab fails to deliver benefit for patients with idiopathic pulmonary fibrosis (IPF) in the phase III ZEPHYRUS-1 trial.

Pamrevlumab disappoints in phase III trial

05 Jul 2024

VTE recurrence in chronic thromboembolic pulmonary hypertension higher with DOACs vs warfarin

05 Jul 2024

For patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving anticoagulation treatment, direct oral anticoagulants (DOACs) appear to yield similar survival and bleeding outcomes but higher risk of venous thromboembolism (VTE) recurrence compared with warfarin, according to a study.

VTE recurrence in chronic thromboembolic pulmonary hypertension higher with DOACs vs warfarin

05 Jul 2024

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

05 Jul 2024 by

Detectable EGFRm in plasma ctDNA prior to treatment may define a subgroup of patients with advanced EGFRm NSCLC who would derive the most benefit from the addition of chemo to 1L osimertinib, according to an exploratory analysis of FLAURA2 presented at AACR 2024

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

05 Jul 2024

9-month, oral modified treatment regimens make the grade in drug-resistant TB

04 Jul 2024 by

Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.

9-month, oral modified treatment regimens make the grade in drug-resistant TB

04 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis

Smoking, occupational dust exposure a risk factor for idiopathic pulmonary fibrosis

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

Certain antipsychotics tied to increased pneumonia risk

Certain antipsychotics tied to increased pneumonia risk

Osimertinib extends PFS by 3.2 years in LAURA

Osimertinib extends PFS by 3.2 years in LAURA

Retrospective study validates nirsevimab role against RSV in infants

Retrospective study validates nirsevimab role against RSV in infants

Pamrevlumab disappoints in phase III trial

Pamrevlumab disappoints in phase III trial

VTE recurrence in chronic thromboembolic pulmonary hypertension higher with DOACs vs warfarin

VTE recurrence in chronic thromboembolic pulmonary hypertension higher with DOACs vs warfarin

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

ctDNA EGFRm helps pinpoint who benefits from 1L osimertinib-chemo combo

9-month, oral modified treatment regimens make the grade in drug-resistant TB

9-month, oral modified treatment regimens make the grade in drug-resistant TB